P21WAF1/CLP1在甲状腺癌组织的表达及临床意义

目的]探讨p21WAF/CLP与p53基因在甲状腺癌中的表达与病理类型和分化程度的关系。方法］应用免疫组化技术检测甲状腺癌组织中的抑癌基因p2lWAF/CLPl及p53基因的表达。统计学采用x2检验。结果]甲状腺腺瘤(TT)，甲状腺乳头状癌(PTC)、滤泡状癌(FTC)、未分化癌(UDC)组织p21蛋白阳性率分别为66.7％、62 5％、58.3％、50.0％，各组之间无显著差别(P＞0.05)；高分化癌(WDC)、低分化癌(PDC)、UDC组织p21蛋白阳性率分别为67.7％、46.2％、50.0％，各组之间无显著差别(P＞0.05)；PTC、FTC、UDC组织p53蛋白阳性率分别为31.3％、25.0％、64.3％，UDC与PTC、FTC之间存在显著差别(P＜0 05)；WDC、PDC、UDC组织p53蛋白阳性率分别为l6.1％、61.5％、64.3％，WDC的阳性率明显低于PDC、UDC(P＜0.05)；p53蛋白阳性的癌组织p21蛋白阳性率为40.9％(9/22)，p53蛋白阴性的癌组织p21蛋白阳性率为69.4％(25/36)，两者之间存在显者差异(P＜0 05)。结论］甲状腺癌中p21WAF/CLP的表达与其病理类型和分化程度无关，而p53基因的表达与甲状腺癌病理类型和分化程度有关，p2WAFl/CLPl作为一新的抑癌基因，其表达相当程度上依赖于p53蛋白。

Expression and Clinical Significance of p21WAF1/CIP1 in Thyroid Carcinoma

Purpose] To investigate expression of p21WAF/CLPl , p53 gene and their relationship with pathologic type and grade in thyroid car-cinoma. Method ] Expression of p21WAFl/CLPl and p53 in thyroid carcinoma was studied by immnunohistochemical technology, and analysed by X2 test.Result] The positive rates of p21 proteins were 62.5%, 58.2%, 50.0% in the papillary thyroid carcinoma (PTC), follicular thyroid carceoma(FTC), and undifferentiated careinoma(UDC) respectively, with no significant difference (P ＞ 0.05 ) to those of well-differentiated carcinoma (WDC.67.7% ), poor-differentiated carcinoma (PDC,46.2%) and UDC(53.0% ).The positive rates of p53 proteins in the PTC ,FTC. UDC were 31.3%,25.0%. 64.3 % respectively. The expression of p53 gene in the UDC were significantly higher than that of PTC and FTC ( P ＜ 0.05). The expressionof p53 gene in the UDC ( 64.3 % ) and PDC (61.5 % ) was significantly higher than that in the WDG ( 16.5 % ) ( P ＜ 0.05 ). The positive rate of p21protein (40.9%) in the p53 positive samples was significantly lower than that in p53 negative samples (69.4%) (P ＜ 0.05) . Conclusion] Thep21WAF/CLPl is a suppressive gene of tumor, and its expression greatly depends on the p53.